Sanofi and Regeneron's Dupixent Approved in the US as the First Biologic Medicine for Young Children With Uncontrolled Chronic Spontaneous Urticaria
April 23, 2026
April 23, 2026
PARIS, France, April 23 -- Sanofi, a life sciences company, issued the following news release on April 22, 2026:
* * *
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
* Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study program
. . .
* * *
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
* Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study program
. . .